ArticleBMJ open2026
Efficacy of electroacupuncture for pain relief in patients with osteonecrosis of the femoral head: protocol for a randomised, triple-blind, sham-controlled trial.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOsteonecrosis of the femoral head (ONFH) is a progressive and disabling condition, with pain being its predominant symptom. Electroacupuncture (EA) has shown promise in the management of chronic pain; however, high-quality evidence on its efficacy and safety in ONFH is still lacking. The aim of this trial is to evaluate the efficacy and safety of EA for pain relief in ONFH. METHODS AND ANALYSIS: This triple-blind, sham-controlled, parallel-group randomised controlled trial will be conducted at a single centre in China and will include 176 participants with ONFH. Participants will be randomly allocated (1:1) to receive either active EA or sham EA. The active intervention involves EA applied to specific acupoints (GB30, GB29, ST31, BL54 and Ashi points) twice weekly for 4 weeks. Sham EA consists of superficial needling at non-acupoint locations using a deactivated device. The primary outcome is the proportion of patients achieving a clinically meaningful reduction in pain at 4 weeks (end of treatment). Secondary outcomes are changes in the Visual Analogue Scale score, the proportion of participants achieving clinically significant pain improvement at weeks 8, 12 and 16, modified Harris Hip Score, psychological scales (Patient Health Questionnaire-9, Generalised Anxiety Disorder-7, Pain Catastrophising Scale, Pain Self-Efficacy Questionnaire), the 12-Item Short Form Health Survey, pain sensitisation tests, rescue analgesic use and the incidence of adverse events. Data will be analysed using the intention-to-treat principle, and appropriate statistical models will be used to compare the primary outcome between groups. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Luoyang Orthopedic Hospital of Henan Province (Approval No: 2025ZXKT0001-02). Written informed consent will be obtained from all participants prior to enrolment. The results of this trial will be disseminated regardless of the findings through publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ISRCTN15751942.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.